Your browser doesn't support javascript.
loading
Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia.
Shea, Lauren K; Mikhail, Fady M; Forero-Torres, Andres; Davis, Randall S.
Afiliación
  • Shea LK; Department of Medicine University of Alabama at Birmingham Birmingham Alabama.
  • Mikhail FM; Department of Genetics University of Alabama at Birmingham Birmingham Alabama.
  • Forero-Torres A; Department of Medicine University of Alabama at Birmingham Birmingham Alabama.
  • Davis RS; Comprehensive Cancer Center University of Alabama at Birmingham Birmingham Alabama.
Clin Case Rep ; 5(6): 899-901, 2017 06.
Article en En | MEDLINE | ID: mdl-28588835
The availability of kinase and other small-molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Case Rep Año: 2017 Tipo del documento: Article